TRUTAKNA

This brand name is authorized in United States.

Active ingredients

The drug TRUTAKNA contains one active pharmaceutical ingredient (API):

`1`	Atacicept UNII `K3D9A0ICQ3` - ATACICEPT
	Atacicept is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. Atacicept, a BLyS-specific inhibitor and APRIL blocker, is a TACI-Fc fusion glycoprotein that binds B cell activating factor (BAFF) and APRIL with dissociation constants (Kd) of 106 pM and 33 pM, respectively, and reduces BAFF- and APRIL-mediated signaling. BAFF is also known as BlyS. Reduction in BAFF- and APRIL-mediated signaling decreases production of serum galactose-deficient IgA1 (Gd-IgA1), which is implicated in the pathophysiology of IgAN.
	Read more about Atacicept

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
TRUTAKNA Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
US	FDA, National Drug Code	85052-101

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.